Desh Rakshak Aushdhalaya Limited

BSE:531521 Stock Report

Market Cap: ₹32.4m

Desh Rakshak Aushdhalaya Valuation

Is 531521 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 531521 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 531521's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 531521's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 531521?

Other financial metrics that can be useful for relative valuation.

531521 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.4x
Enterprise Value/EBITDA5.4x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does 531521's PE Ratio compare to its peers?

The above table shows the PE ratio for 531521 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average33.2x
543444 Fabino Life Sciences
68.1xn/a₹61.1m
531210 Colinz Laboratories
21.8xn/a₹104.5m
543500 Evoq Remedies
10.5xn/a₹143.1m
524400 Ishita Drugs and Industries
32.4xn/a₹209.3m
531521 Desh Rakshak Aushdhalaya
8.5xn/a₹32.4m

Price-To-Earnings vs Peers: 531521 is good value based on its Price-To-Earnings Ratio (8.5x) compared to the peer average (33.2x).


Price to Earnings Ratio vs Industry

How does 531521's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a18.8%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a18.8%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: 531521 is good value based on its Price-To-Earnings Ratio (8.5x) compared to the Indian Pharmaceuticals industry average (34.9x).


Price to Earnings Ratio vs Fair Ratio

What is 531521's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

531521 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio8.5x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 531521's Price-To-Earnings Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.